Psilocybin for Treatment of Prolonged Grief Disorder: An Open-Label Feasibility Study Protocol
Psychoactives April 13, 2026 J. Morgan Penberthy, Fatma Wise, Nicholas P. Cherup et al.
Prolonged grief disorder (PGD) affects approximately 10% of bereaved individuals and is now formally recognized in both the DSM-5-TR and ICD-11. Despite its prevalence, PGD often responds poorly to traditional therapeutic approaches. This manuscript outlines the protocol for an early-stage open-label feasibility trial investigating the use of psilocybin, a psychedelic compound, in treating PGD...